The Latest Breaking News from BMY

It's a new day at Bristol Myers, according to a company exec. But the drug giant's stock remains under pressure ahead of a patent cliff.

Monthly inflation inched up in January. Moreover, the Fed could be forced to raise the benchmark rate higher than forecasted. Amid this backdrop, it could be wise for investors to buy fundamentally strong stocks Coca-Cola (KO), Bristol-Myers Squibb (BMY), Cardinal Health (CAH), and Bluegreen Vacations Holding (BVH), currently trading under…

Although favorable macro data rekindled investor optimism, the Fed’s intention of raising rates to tame stubbornly high inflation could possibly tip the economy into recession. With anxiety escalating, it would be wise to add quality stocks Johnson & Johnson (JNJ) and Bristol-Myers Squibb (BMY) to your portfolio to sail through…

Cooling inflationary pressures, a slowdown in the Fed’s interest rate hikes, and easing recession fears are contributing to improved investor sentiment lately. Amid growing investor optimism, fundamentally sound stocks Bristol-Myers Squibb (BMY) and General Motors (GM) could be wise additions to your portfolio to start 2023 right. Continue reading….

The pharmaceutical industry is well-positioned for significant growth in the near future, given the growing demand for medicines and increasing R&D activities. Given the industry's inelastic demand, fundamentally strong pharma stocks AstraZeneca (AZN), Bristol-Myers Squibb (BMY), and GSK plc (GSK) might be solid long-term investments. Continue reading….

Bristol's Revlimid took fewer than expected generic hits in the fourth quarter, resulting in a beat and a pop for BMY stock Thursday.

Consistently falling prices and stronger-than-expected fourth-quarter GDP are renewing hopes about the economy’s overall health. Therefore, it could be wise to add quality stocks with solid fundamentals, Walmart (WMT), Bristol-Myers Squibb (BMY), and CVS Health (CVS), to your portfolio to garner substantial returns in 10 years. Read more….

The Fed’s indication to keep raising interest rates through this year and looming recession fears will likely keep the stock market under pressure for the near term. Therefore, investors looking for stability amid an uncertain macroeconomic environment could consider buying fundamentally strong dividend-paying healthcare stocks Johnson & Johnson (JNJ), Pfizer…

The incessant rate hikes have led to significant market volatility and raised recessionary fears. However, with inflation finally cooling and wage growth slowing down, we think fundamentally strong stocks Bristol-Myers Squibb (BMY), Cardinal Health (CAH), and KT Corp (KT), which are rated A (Strong Buy) in our proprietary rating system,…

Inflation eased for the second consecutive month in November, and the Fed slowed down the pace of rate hikes after four straight 75-basis-point hikes. However, recession fears loom as the central bank plans to raise rates through next year. Regardless of the economic uncertainties, it could be wise to invest…

Despite macroeconomic challenges, leading pharma company Bristol-Myers Squibb (BMY) has the robustness and resilience to deliver value for shareholders. Read on….